Accepted for Publication: April 3, 2012.
Published Online: August 6, 2012. doi:10.1001/archneurol.2012.1092
Author Contributions:Study concept and design: Siepmann, Gibbons, Lafo, Brown, and Freeman. Acquisition of data: Siepmann, Gibbons, Illigens, Lafo, Brown, and Freeman. Analysis and interpretation of data: Siepmann, Gibbons, Illigens, Lafo, and Freeman. Drafting of the manuscript: Siepmann, Gibbons, Illigens, and Freeman. Critical revision of the manuscript for important intellectual content: Siepmann, Gibbons, Illigens, Lafo, Brown, and Freeman. Statistical analysis: Siepmann and Gibbons. Obtained funding: Gibbons and Freeman. Administrative, technical, and material support: Siepmann, Illigens, Lafo, Brown, and Freeman. Study supervision: Siepmann, Gibbons, Illigens, and Freeman.
Conflict of Interest Disclosures: Dr Siepmann's work is funded by grant Si 1589/1-1 from the German Research Foundation. Dr Gibbons' work is funded by grant K23 NS050209 from the National Institutes of Health. Dr Freeman has served on scientific advisory boards of Abbott Laboratories, Bristol-Myers Squibb, Chelsea Therapeutics, Eli Lilly, Grunenthal, GlaxoSmithKline, Pfizer, sanofi-aventis, and XenoPort. He has also received grants R01 HL059459, R01HL109634, and U54 NS065736 from the National Institutes of Health, as well as personal compensation for his editorial activities as an editor with Autonomic Neuroscience: Basic and Clinical and the Clinical Journal of Pain.
Funding/Support: This study was funded by grant K23 NS050209 to Dr Gibbons from the National Institutes of Health and support from the Langer Family Foundation.